Extract Pulmonary arterial hypertension (PAH) is a chronic, progressive disease in which increased pulmonary vascular resistance (PVR) and elevated mean pulmonary arterial pressure (mPAP) lead to right ventricular (RV) dysfunction, the major determinant of mortality 1. Although advances in targeted therapies have improved survival, pragmatic and clinically meaningful haemodynamic treatment goals remain needed 2. Reductions in PVR and mPAP correlate with RV recovery and better long-term outcomes, as described after the initiation of pulmonary vasodilators and specially after lung transplant in PAH, and in the context of chronic thromboembolic pulmonary hypertension after successful interventional treatment 3, 4, 5. The concept of haemodynamic partial remission (PR)—a profound reduction of afterload without full normalisation—has gained interest, but its prevalence and prognostic relevance have not been well defined 6. This study evaluates PR in a large contemporary cohort of patients with PAH.
Cruz-Utrilla et al. (Thu,) studied this question.